|
New CLL Therapy Beats Standard Protocol
MedPage Today The findings suggest that the new drug is “equally safe yet more powerful” than rituximab, commented Jennifer Brown, MD, PhD, of the Dana-Farber Cancer Institute in Boston, who was not involved in the study but who moderated a press conference at which … |
CCS issues guidelines to improve early diagnosis & effective treatment of … – EurekAlert (press release)
|
CCS issues guidelines to improve early diagnosis & effective treatment of …
EurekAlert (press release) Philadelphia, PA, December 11, 2013 – Heart failure in children is an important cause of childhood health problems and death. The Children’s Heart Failure Study Group of the Canadian Cardiovascular Society, in collaboration with the Canadian Pediatric … |
Hyperphosphatemia in Chronic Kidney Disease – Pipeline Review, H2 2013 – SBWire (press release)
|
Hyperphosphatemia in Chronic Kidney Disease – Pipeline Review, H2 2013
SBWire (press release) ‘Hyperphosphatemia In Chronic Kidney Disease – Pipeline Review, H2 2013′, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hyperphosphatemia In Chronic Kidney Disease, … |
Data on Monoclonal Antibodies Detailed by Researchers at University Health … – HispanicBusiness.com
|
Data on Monoclonal Antibodies Detailed by Researchers at University Health …
HispanicBusiness.com By a News Reporter-Staff News Editor at Women’s Health Weekly — Fresh data on Drugs and Therapies are presented in a new report. According to news reporting from Toronto, Canada , by NewsRx journalists, research stated, “Block copolymer micelles … |
Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLL – Cancer Network
|
Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLL
Cancer Network The progression-free survival (PFS) rate at 24 weeks was 93% for patients treated with idelalisib plus rituximab compared with 46% for patients treated with rituximab alone. The median PFS of the combination arm has not yet been reached. The median PFS … Idelalisib plus rituximab extended survival in previously treated CLLHealio Gilead’s Pipeline EncouragesYahoo News |
Treating heart failure with exercise – how much is enough? – YottaFire
|
Treating heart failure with exercise – how much is enough?
YottaFire OptimEx, a new 3.5-year study funded by the European Union and coordinated by the Norwegian University of Science and Technology (NTNU), will look at whether exercise could be used both to prevent and treat a specific type of heart failure. More than … |
“Lots Of Cheques Donated Bounced” | OJB Jezreel Opens Up to Hip TV about … – Bella Naija
|
“Lots Of Cheques Donated Bounced” | OJB Jezreel Opens Up to Hip TV about …
Bella Naija OJB Jezreel’s kidney transplant surgery has created a lot of media buzz over the past few months. After series of donations to the cause, the veteran jetted off to India for the critical procedure. Good news! It’s over now and the veteran musician has … |
Innovative Program Doubles Patient Engagement, Cuts Heart Failure … – Virtual-Strategy Magazine (press release)
|
Innovative Program Doubles Patient Engagement, Cuts Heart Failure …
Virtual-Strategy Magazine (press release) SEATTLE, Dec. 11, 2013 /PRNewswire/ — A San Diego medical group’s disease management program increased patient engagement rates from 28% to 67%, leading to a decline in both hospitalizations and 30-day readmissions for program participants. |
Treasure Coast Christmas Events, updated Dec. 11 – TCPalm
|
Treasure Coast Christmas Events, updated Dec. 11
TCPalm Holidays at McKee: Vintage Wurlitzer band organ playing classic holiday music, model trains, holiday letter writing, visits with Santa, Mrs. Claus’ Serendipity Candy Shop, lights, decorations. 6-8 p.m. Dec. 21-23. … Bring unwrapped toy or monetary … |
Idelalisib plus rituximab extended survival in previously treated CLL – Healio
|
Idelalisib plus rituximab extended survival in previously treated CLL
Healio NEW ORLEANS — The addition of idelalisib to rituximab significantly extended survival in heavily pretreated patients with relapsed chronic lymphocytic leukemia, according to phase 3 study results presented at the ASH Annual Meeting and Exposition. Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLLCancer Network Gileads Pipeline EncouragesZacks.com |